SpinalCyte Rebrands to FibroGenesis

SpinalCyte introduced a new company name, FibroGenesis, reflecting its intellectual property portfolio that includes a treatment for degenerative disc disease (DDD) and other chronic diseases.

The company's CybroCell™ is reportedly the first off-the-shelf allogenic human dermal fibroblast product for the treatment of DDD. In...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0